BRD4 Silencing Protects Angiotensin II-Induced Cardiac Hypertrophy by Inhibiting TLR4/NF-κB and Activating Nrf2-HO-1 Pathways

Background. Heart failure is a critical health problem worldwide, and cardiac hypertrophy is an important characteristic of heart failure. Bromodomain-containing protein 4 (BRD4) is involved in various cellular processes, including cardiac hypertrophy. This study aimed to investigate the mechanism u...

Full description

Saved in:
Bibliographic Details
Main Authors: Ming Fang, Jun Luo, Xi Zhu, Yingbiao Wu, Xinming Li
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Cardiology Research and Practice
Online Access:http://dx.doi.org/10.1155/2022/8372707
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850120424869855232
author Ming Fang
Jun Luo
Xi Zhu
Yingbiao Wu
Xinming Li
author_facet Ming Fang
Jun Luo
Xi Zhu
Yingbiao Wu
Xinming Li
author_sort Ming Fang
collection DOAJ
description Background. Heart failure is a critical health problem worldwide, and cardiac hypertrophy is an important characteristic of heart failure. Bromodomain-containing protein 4 (BRD4) is involved in various cellular processes, including cardiac hypertrophy. This study aimed to investigate the mechanism underlying the effects of BRD4 on cardiac hypertrophy. Methods. Rat myoblast H9c2 cells were treated with angiotensin II (Ang II) to increase the mRNA and protein expressions of BRD4. BRD4 was silenced by small interfering RNA (siRNA) in H9c2 cells. Proteins involved in Nrf2-HO-1 pathway were determined by Western blot. Results. Our data suggest that BRD4 silencing attenuated Ang II, increased the percentage of TUNEL + cells and caspase-3 activity, increased oxidative stress, and increased the expression and content of pro-inflammatory cytokines. Mechanistically, we found that BRD4 silencing enhanced the protein expressions of Nrf2 and HO-1 and inhibited the TLR4 and phosphorylation of NF-kappa B in Ang II-stimulated H9c2 cells. TLR4 overexpression attenuated cardioprotection against Ang II by BRD4 silencing, including cardiac hypertrophy, oxidative stress, and inflammatory cytokine production. Additionally, TLR4 overexpression attenuated an increase in Nrf2 and HO-1 proteins and decreased phosphorylated NF-kappa B in H9c2 cells. Conclusion. Our results speculate that the BRD4/TLR4 axis might be a promising strategy for treating cardiovascular diseases with cardiac hypertrophy, including HF.
format Article
id doaj-art-613255f2275848ea97cf19f0640890a1
institution OA Journals
issn 2090-0597
language English
publishDate 2022-01-01
publisher Wiley
record_format Article
series Cardiology Research and Practice
spelling doaj-art-613255f2275848ea97cf19f0640890a12025-08-20T02:35:21ZengWileyCardiology Research and Practice2090-05972022-01-01202210.1155/2022/8372707BRD4 Silencing Protects Angiotensin II-Induced Cardiac Hypertrophy by Inhibiting TLR4/NF-κB and Activating Nrf2-HO-1 PathwaysMing Fang0Jun Luo1Xi Zhu2Yingbiao Wu3Xinming Li4Department of CardiologyDepartment of CardiologyDepartment of CardiologyDepartment of CardiologyDepartment of CardiologyBackground. Heart failure is a critical health problem worldwide, and cardiac hypertrophy is an important characteristic of heart failure. Bromodomain-containing protein 4 (BRD4) is involved in various cellular processes, including cardiac hypertrophy. This study aimed to investigate the mechanism underlying the effects of BRD4 on cardiac hypertrophy. Methods. Rat myoblast H9c2 cells were treated with angiotensin II (Ang II) to increase the mRNA and protein expressions of BRD4. BRD4 was silenced by small interfering RNA (siRNA) in H9c2 cells. Proteins involved in Nrf2-HO-1 pathway were determined by Western blot. Results. Our data suggest that BRD4 silencing attenuated Ang II, increased the percentage of TUNEL + cells and caspase-3 activity, increased oxidative stress, and increased the expression and content of pro-inflammatory cytokines. Mechanistically, we found that BRD4 silencing enhanced the protein expressions of Nrf2 and HO-1 and inhibited the TLR4 and phosphorylation of NF-kappa B in Ang II-stimulated H9c2 cells. TLR4 overexpression attenuated cardioprotection against Ang II by BRD4 silencing, including cardiac hypertrophy, oxidative stress, and inflammatory cytokine production. Additionally, TLR4 overexpression attenuated an increase in Nrf2 and HO-1 proteins and decreased phosphorylated NF-kappa B in H9c2 cells. Conclusion. Our results speculate that the BRD4/TLR4 axis might be a promising strategy for treating cardiovascular diseases with cardiac hypertrophy, including HF.http://dx.doi.org/10.1155/2022/8372707
spellingShingle Ming Fang
Jun Luo
Xi Zhu
Yingbiao Wu
Xinming Li
BRD4 Silencing Protects Angiotensin II-Induced Cardiac Hypertrophy by Inhibiting TLR4/NF-κB and Activating Nrf2-HO-1 Pathways
Cardiology Research and Practice
title BRD4 Silencing Protects Angiotensin II-Induced Cardiac Hypertrophy by Inhibiting TLR4/NF-κB and Activating Nrf2-HO-1 Pathways
title_full BRD4 Silencing Protects Angiotensin II-Induced Cardiac Hypertrophy by Inhibiting TLR4/NF-κB and Activating Nrf2-HO-1 Pathways
title_fullStr BRD4 Silencing Protects Angiotensin II-Induced Cardiac Hypertrophy by Inhibiting TLR4/NF-κB and Activating Nrf2-HO-1 Pathways
title_full_unstemmed BRD4 Silencing Protects Angiotensin II-Induced Cardiac Hypertrophy by Inhibiting TLR4/NF-κB and Activating Nrf2-HO-1 Pathways
title_short BRD4 Silencing Protects Angiotensin II-Induced Cardiac Hypertrophy by Inhibiting TLR4/NF-κB and Activating Nrf2-HO-1 Pathways
title_sort brd4 silencing protects angiotensin ii induced cardiac hypertrophy by inhibiting tlr4 nf κb and activating nrf2 ho 1 pathways
url http://dx.doi.org/10.1155/2022/8372707
work_keys_str_mv AT mingfang brd4silencingprotectsangiotensiniiinducedcardiachypertrophybyinhibitingtlr4nfkbandactivatingnrf2ho1pathways
AT junluo brd4silencingprotectsangiotensiniiinducedcardiachypertrophybyinhibitingtlr4nfkbandactivatingnrf2ho1pathways
AT xizhu brd4silencingprotectsangiotensiniiinducedcardiachypertrophybyinhibitingtlr4nfkbandactivatingnrf2ho1pathways
AT yingbiaowu brd4silencingprotectsangiotensiniiinducedcardiachypertrophybyinhibitingtlr4nfkbandactivatingnrf2ho1pathways
AT xinmingli brd4silencingprotectsangiotensiniiinducedcardiachypertrophybyinhibitingtlr4nfkbandactivatingnrf2ho1pathways